DIA
Drug Information Association Logo

HEALTH ECONOMIC ASPECTS OF PERSONALISED MEDICINE

Track:
Personalised Medicine: Drug-companion diagnostics combinations

Day & Time:
March 26, 2:00PM - 3:30PM (Central European Standard Time)

Session Number:
0503

Room Number:
Room I

Type:
Session

Title:
HEALTH ECONOMIC ASPECTS OF PERSONALISED MEDICINE

Chair(s):
Sabine Vogler, PhD
Head of Pharma Team, Head of WHO Collaborating Centre
Gesundheit Österreich GmbH, Austria

Description:
Personalised medicine approaches aim at assuring optimal use of healthcare budgets by only providing a therapy to those patients that benefit from the treatment. However this approach drives towards many different and often more expensive treatments. This session will address the question: How to make personalised medicine affordable?

Presentation(s) & Speaker(s):
Pre-empting Problems for Personalised Medicine Adoption in the Market
Brian Godman, PhD
Senior Researcher
Karolinska Institutet, Sweden

European Payers Overview on Reimbursement
Claudia Habl
Head of Austrian Pharmaceutical Price Information (PPI-Service)
Austrian Health Institute (Gesundheit Österreich Gmbh), Austria

The Importance to Value Diagnostics
Yullie Matsouka
Vice President Medical Shared Services
Roche Diagnostics International, Switzerland

Balancing Public and Private Interests in the Insured Package
Martin van der Graaff
Health Care Insurance Board (CVZ), Netherlands